About this study
Australia's ageing population is a significant concern facing contemporary society. The ageing process can bring decreased productivity, a higher incidence of conditions such as cardiovascular and respiratory disease and neurological conditions such as Parkinson's and Alzheimer's.
Age-related changes to our cognitive abilities occur simultaneously with cellular degradation in the brain. Strong indications of a relationship between the onset of cognitive decline and progressive damage to the brain provides a case for protective initiatives.
The study will:
- examine the effects of 52-week doses of Bacopa, Pycnogenol and micronutrient combination formulas (or placebo) on memory, cognitive performance and metabolic function in healthy adults aged 60–75 years
- investigate the time course of the above measures with follow-up at three, six and twelve months after commencement of interventions
- identify health and lifestyle variables that influence health outcomes, such as perceived stress, mood, physical exercise, sleep quality, diet and nutrient levels, and personality
- examine brain neurophysiological change through functional brain imaging (as an optional component for participants) in the first three months after intervention
- explore mechanisms underpinning cognitive and cardiovascular enhancement through detailed cardiovascular (blood pressure and arterial stiffness), biochemical (safety, oxidative stress and inflammation) and genetic analysis (telomere length and key Single Nucleotide Polymorphisms related to brain function and health).
This trial has finished recruitment and study findings will be available soon.